Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

Higher BMI and IBD causally increase hidradenitis suppurativa risk, large study finds, providing actionable insights for ...

A rare condition called Eosinophilic Fasciitis caused a 42-year-old engineer severe pain and stiffness. Doctors identified ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

New genetic evidence links higher BMI and IBD to hidradenitis suppurativa risk, while smoking remains unclear. Read more.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...